Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV

Autores
Laufer, Natalia Lorna; Rockstroh, Jürgen Kurt
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Chronic HCV infection affects 130-170 million individuals worldwide and there are currently 34 million people living with HIV/AIDS. The aim of treatment of HCV is the elimination of the virus (sustained virological response). With development of drugs that specifically target HCV replication, direct-acting agents, sustained virological response rates have dramatically changed for genotype 1 infections. Challenges in the use of direct-acting agents in patients with HIV/HCV co-infection include the potential for drug-drug interactions between HIV and HCV drugs, additional drug toxicities and the need for therapy with IFN-α. Faldaprevir (FDV), previously known as BI 201335, is a second-wave HCV NS3/4A protease inhibitor with highly potent in vitro activity against HCV GT-1a/1b and improved pharmacokinetics suitable for once-daily dosing. FDV is currently in Phase III development. This article will review the pharmacology and pharmacodynamics of FDV, the efficacy and safety of the drug and explore possible future developments in the management of chronic hepatitis C infection, focusing on HIV/HCV co-infected patients. © 2014 Informa UK Ltd.
Fil: Laufer, Natalia Lorna. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
Fil: Rockstroh, Jürgen Kurt. Universitat Bonn; Alemania
Materia
FALDAPREVIR
HEPATITIS C
HIV
TREATMENT
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/91357
Acceder
id CONICETDig_16e701f3eb86707e0624f5e11de7797b
oai_identifier_str oai:ri.conicet.gov.ar:11336/91357
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIVLaufer, Natalia LornaRockstroh, Jürgen KurtFALDAPREVIRHEPATITIS CHIVTREATMENThttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Chronic HCV infection affects 130-170 million individuals worldwide and there are currently 34 million people living with HIV/AIDS. The aim of treatment of HCV is the elimination of the virus (sustained virological response). With development of drugs that specifically target HCV replication, direct-acting agents, sustained virological response rates have dramatically changed for genotype 1 infections. Challenges in the use of direct-acting agents in patients with HIV/HCV co-infection include the potential for drug-drug interactions between HIV and HCV drugs, additional drug toxicities and the need for therapy with IFN-α. Faldaprevir (FDV), previously known as BI 201335, is a second-wave HCV NS3/4A protease inhibitor with highly potent in vitro activity against HCV GT-1a/1b and improved pharmacokinetics suitable for once-daily dosing. FDV is currently in Phase III development. This article will review the pharmacology and pharmacodynamics of FDV, the efficacy and safety of the drug and explore possible future developments in the management of chronic hepatitis C infection, focusing on HIV/HCV co-infected patients. © 2014 Informa UK Ltd.Fil: Laufer, Natalia Lorna. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; ArgentinaFil: Rockstroh, Jürgen Kurt. Universitat Bonn; AlemaniaTaylor & Francis2014-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/91357Laufer, Natalia Lorna; Rockstroh, Jürgen Kurt; Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV; Taylor & Francis; Expert Review of Anti-infective Therapy; 12; 2; 2-2014; 157-1641478-7210CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.1586/14787210.2014.868774?journalCode=ierz20info:eu-repo/semantics/altIdentifier/doi/10.1586/14787210.2014.868774info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:46:11Zoai:ri.conicet.gov.ar:11336/91357instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:46:12.562CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV
title Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV
spellingShingle Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV
Laufer, Natalia Lorna
FALDAPREVIR
HEPATITIS C
HIV
TREATMENT
title_short Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV
title_full Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV
title_fullStr Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV
title_full_unstemmed Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV
title_sort Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV
dc.creator.none.fl_str_mv Laufer, Natalia Lorna
Rockstroh, Jürgen Kurt
author Laufer, Natalia Lorna
author_facet Laufer, Natalia Lorna
Rockstroh, Jürgen Kurt
author_role author
author2 Rockstroh, Jürgen Kurt
author2_role author
dc.subject.none.fl_str_mv FALDAPREVIR
HEPATITIS C
HIV
TREATMENT
topic FALDAPREVIR
HEPATITIS C
HIV
TREATMENT
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Chronic HCV infection affects 130-170 million individuals worldwide and there are currently 34 million people living with HIV/AIDS. The aim of treatment of HCV is the elimination of the virus (sustained virological response). With development of drugs that specifically target HCV replication, direct-acting agents, sustained virological response rates have dramatically changed for genotype 1 infections. Challenges in the use of direct-acting agents in patients with HIV/HCV co-infection include the potential for drug-drug interactions between HIV and HCV drugs, additional drug toxicities and the need for therapy with IFN-α. Faldaprevir (FDV), previously known as BI 201335, is a second-wave HCV NS3/4A protease inhibitor with highly potent in vitro activity against HCV GT-1a/1b and improved pharmacokinetics suitable for once-daily dosing. FDV is currently in Phase III development. This article will review the pharmacology and pharmacodynamics of FDV, the efficacy and safety of the drug and explore possible future developments in the management of chronic hepatitis C infection, focusing on HIV/HCV co-infected patients. © 2014 Informa UK Ltd.
Fil: Laufer, Natalia Lorna. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; Argentina
Fil: Rockstroh, Jürgen Kurt. Universitat Bonn; Alemania
description Chronic HCV infection affects 130-170 million individuals worldwide and there are currently 34 million people living with HIV/AIDS. The aim of treatment of HCV is the elimination of the virus (sustained virological response). With development of drugs that specifically target HCV replication, direct-acting agents, sustained virological response rates have dramatically changed for genotype 1 infections. Challenges in the use of direct-acting agents in patients with HIV/HCV co-infection include the potential for drug-drug interactions between HIV and HCV drugs, additional drug toxicities and the need for therapy with IFN-α. Faldaprevir (FDV), previously known as BI 201335, is a second-wave HCV NS3/4A protease inhibitor with highly potent in vitro activity against HCV GT-1a/1b and improved pharmacokinetics suitable for once-daily dosing. FDV is currently in Phase III development. This article will review the pharmacology and pharmacodynamics of FDV, the efficacy and safety of the drug and explore possible future developments in the management of chronic hepatitis C infection, focusing on HIV/HCV co-infected patients. © 2014 Informa UK Ltd.
publishDate 2014
dc.date.none.fl_str_mv 2014-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/91357
Laufer, Natalia Lorna; Rockstroh, Jürgen Kurt; Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV; Taylor & Francis; Expert Review of Anti-infective Therapy; 12; 2; 2-2014; 157-164
1478-7210
CONICET Digital
CONICET
url http://hdl.handle.net/11336/91357
identifier_str_mv Laufer, Natalia Lorna; Rockstroh, Jürgen Kurt; Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV; Taylor & Francis; Expert Review of Anti-infective Therapy; 12; 2; 2-2014; 157-164
1478-7210
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.1586/14787210.2014.868774?journalCode=ierz20
info:eu-repo/semantics/altIdentifier/doi/10.1586/14787210.2014.868774
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842268777175056384
score 13.13397

Publicaciones similares